Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025European Heart Journal Supplements

Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRodrigo CarrascoIAInbar Nardi AgmonFFFarid Foroutan

Discussion

Loading...

Member takes

Overview

This systematic review assesses cardiovascular adverse events in cancer patients undergoing CAR-T, BiTEs, and TILs, indicating the need for careful monitoring.

Key Points

  • The meta-analysis includes 107 studies assessing cardiovascular adverse events in CAR-T, BiTEs, and TILs therapies.
  • Cytokine release syndrome was highest in CAR-T therapy at 85.7%, contrasting sharply with TILs and BiTEs.
  • Heart failure incidence was low at 1.1% within 30 days, with no differences across therapy types.
  • Arrhythmias were reported at 4.6% in the first 30 days, showing a need for ongoing monitoring in observational studies.

Cite This Study

Carrasco et al. (2025) studied this question.

synapsesocial.com/papers/689a0c65e6551bb0af8cf983https://doi.org/10.1093/eurheartjsupp/suaf083.016
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of cardiotoxicity with chimeric antigen receptor T-cell (CAR-T) therapy: A systematic review.2026
  2. 2Cardiovascular adverse events in patients with cancer treated with chimeric antigen receptor (CAR) T-cell therapy: A meta-analysis of both controlled and single-arm clinical trials.2024 · 2 citations
  3. 3Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis2022 · 23 citations
  4. 4Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)2019 · 357 citations
  5. 5Cardiovascular implications of CAR-T cell therapy: insights from a regional cardio-oncology program2025